| Description: |
Menglan Zhai,1,* Jianping Bi,1,* Zirui Ke,2,3,* Min Hu,4 Guoliang Pi,1 Ying Li,1 Hanping He,1 Yanping Li,1 Hongmei Zheng,2,3 Xinhong Wu,2,3 Vivek Verma,5 Jun Shao,2,3 Guang Han1 1Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 2Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Key Clinical Specialty, Wuhan, Hubei, People’s Republic of China; 3Wuhan Clinical Research Center for Breast Cancer, Hubei Provincial Clinical Research Center for Breast Cancer, Wuhan, Hubei, People’s Republic of China; 4Department of Pathology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China; 5Department of Radiation Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA*These authors contributed equally to this workCorrespondence: Guang Han, Department of Radiation Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, People’s Republic of China, Tel +86-27-8767-0023, Email hg7913@hotmail.com Jun Shao, Department of Breast Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, National Key Clinical Specialty, Wuhan, Hubei, People’s Republic of China, Tel +86-27-8767-0051, Email 39390822@qq.comPurpose: The combination of radiotherapy with immunotherapy holds synergistic potential, yet its role in the neoadjuvant treatment of breast cancer remains underexplored. This single-center, retrospective pilot study aimed to explore the preliminary efficacy and safety of integrating stereotactic body radiotherapy (SBRT) with chemoimmunotherapy as a novel neoadjuvant regimen for a small cohort of patients with high-risk, locally advanced breast cancer.Patients and Methods: Between June ... |